Development of a hybrid paclitaxel-loaded arsenite nanoparticle (HPAN) delivery system for synergistic combined therapy of paclitaxel-resistant cancer

Chen, Fei-yan; Chen, Xiangyu; Li, Jia-qian; Xiao, Xiaoping; Yu, Lulu; Tang, Qun

doi:10.1007/s11051-017-3848-0

Cited by 8 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the drug release of nano-drugs in lysosome is in a controllable manner. Hence, they can reduce the drug resistance of cancer cells and kill cancer cells more effectively [30,31]. These results indicate that ALNPs are a potentially potent hepatocellular carcinoma chemotherapy agent.…”

Section: Resultsmentioning

confidence: 82%

Arsenite-loaded nanoparticles inhibit the invasion and metastasis of a hepatocellular carcinoma:in vitroandin vivostudy

et al. 2017

View full text Add to dashboard Cite

Postoperative recurrence and metastasis are the major problems for the current treatment of hepatocellular carcinomas (HCC) in the clinic, including hepatectomy and liver transplantation. Here, we report that arsentic-loaded nanoparticles (ALNPs) are able to reduce the invasion of HCC cells in vitro, and, more importantly, can strongly suppress the invasion and metastasis of HCC in vivo without adverse side effects. Compared to free drug arsenic trioxide , ALNPs can deliver the drug into cancer cells more efficiently, destroy the structure of microtubules and reduce the aggregation of microfilaments in cell membranes more significantly. Furthermore, our results also reveal that tumor cells in murine blood were reduced remarkably after intravenous injection of ALNPs, indicating that this nano-drug may efficiently kill circulating tumor cells in vivo. In conclusion, our nano-drug ALNPs have great potential for the suppression of metastasis of HCC, which may open up a new avenue for the effective treatment of HCC without metastasis and recurrence.

show abstract

Section: Resultsmentioning

confidence: 82%

Arsenite-loaded nanoparticles inhibit the invasion and metastasis of a hepatocellular carcinoma:in vitroandin vivostudy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Nanocarriers with distinct advantages and multiple functionalities can serve as potential candidates to address the above issues (Chen et al 2017;Zhang et al 2015a, b). The encapsulation of chemotherapeutic agents, such as doxorubicin and daunorubicin, in nanocarriers facilitates the bypass of efflux-pump in resistant cells (Meng et al 2013;Zhu et al 2014;Kirtane et al 2013;Loos et al 2014).…”

Section: Introductionmentioning

confidence: 99%

Dual drug-loaded PLA nanoparticles bypassing drug resistance for improved leukemia therapy

Zhang

Zhu

et al. 2019

J Nanopart Res

View full text Add to dashboard Cite

Drug resistance is still a bottleneck hindering successful chemotherapy in leukemia treatment. Nanocarriers have emerged as promising candidates to circumvent drug resistance and discover potent drug combinations. Here, we showed that co-encapsulation of daunorubicin (DNR) and glycyrrhizic acid (GA) in polylactic acid (PLA) nanoparticles effectively bypassed drug resistance and remarkably inhibited the growth of drug-resistant leukemia cells. The quantification of intracellular drug found that the encapsulation effectively increased drug uptake in the resistant K562/ A02 cells. Modification of P-glycoprotein antibody on nanoparticles further enhanced drug accumulation in the leukemia cells, which was also confirmed by fluorescent microscopy imaging. More importantly, loaded in PLA nanoparticles, DNR and GA exerted an excellent synergistic effect, leading to significantly improved cell inhibition compared to the treatments without nanocarriers and those with a single drug. Correlative mechanism study revealed that the drug delivery system drastically enhanced cell apoptosis by regulating apoptotic genes but did not influence MDR1 expression. The present study proposes a versatile strategy to improve the therapeutic efficacy against drug-resistant leukemia and inspires the discovery of more potent drug combinations for enhanced leukemia therapy.

show abstract

An Overview of Paclitaxel Delivery Systems

Prabakaran

Kar

Vignesh

et al. 2020

Sustainable Agriculture Reviews

View full text Add to dashboard Cite

Development of a hybrid paclitaxel-loaded arsenite nanoparticle (HPAN) delivery system for synergistic combined therapy of paclitaxel-resistant cancer

Cited by 8 publications

References 20 publications

Arsenite-loaded nanoparticles inhibit the invasion and metastasis of a hepatocellular carcinoma:in vitroandin vivostudy

Arsenite-loaded nanoparticles inhibit the invasion and metastasis of a hepatocellular carcinoma:in vitroandin vivostudy

Dual drug-loaded PLA nanoparticles bypassing drug resistance for improved leukemia therapy

An Overview of Paclitaxel Delivery Systems

Contact Info

Product

Resources

About